Critical Limb Ischemia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Drugs {Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others}, Devices {Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents}), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.58 Billion
CAGR (2026-2031)	6.76%
Fastest Growing Segment	Embolic Protection Devices
Largest Market	North America
Market Size (2031)	USD 6.78 Billion

Market Overview

The Global Critical Limb Ischemia Treatment Market will grow from USD 4.58 Billion in 2025 to USD 6.78 Billion by 2031 at a 6.76% CAGR. The Global Critical Limb Ischemia Treatment Market comprises medical devices and pharmaceuticals aimed at restoring arterial blood flow in patients with the most advanced stage of peripheral artery disease. Primary drivers fueling market growth include the globally aging demographic and the rising prevalence of diabetes which leads to severe vascular complications and necessitates urgent intervention. According to the American Heart Association, in 2024, peripheral artery disease affected an estimated 236 million individuals globally, indicating a substantial patient population at risk of developing critical ischemic symptoms.

Despite strong demand, the market encounters significant obstacles regarding the clinical efficacy and cost of limb salvage techniques. A major challenge impeding expansion is the high rate of procedural failure that necessitates amputation and results in significant long term disability costs for healthcare systems. This economic and clinical burden creates hesitation among healthcare providers and payers regarding the reimbursement of expensive revascularization therapies for high risk patients with complex anatomical blockage.

Key Market Drivers

Advancements in Minimally Invasive Endovascular Revascularization Techniques are revolutionizing the treatment landscape by addressing the limitations of traditional angioplasty in below-the-knee interventions. Manufacturers are heavily investing in novel scaffolds and intravascular lithotripsy devices that offer superior vessel patency and reduce restenosis rates for patients with complex arterial blockages. A pivotal development in this space is the commercialization of drug-eluting resorbable scaffolds, which support the vessel during healing before dissolving to prevent permanent metallic caging. According to Abbott, April 2024, in the 'Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee' press release, the Esprit BTK System demonstrated a primary efficacy endpoint of 74.5% freedom from amputation, occlusion, or revascularization at one year, significantly outperforming the 43.7% observed in the control group. This technological trajectory has triggered substantial industrial consolidation, as major strategics move to acquire specialized limb salvage portfolios. According to Johnson & Johnson, in 2024, the company entered a definitive agreement to acquire Shockwave Medical for an enterprise value of approximately $13.1 billion, validating the immense market value placed on technologies capable of treating calcified peripheral lesions.

The Rising Global Prevalence of Diabetes and Peripheral Artery Disease acts as the foundational driver for market volume, necessitating urgent limb-preservation strategies to mitigate high amputation rates. As the diabetic population expands, the incidence of chronic limb-threatening ischemia escalates, creating a critical need for effective therapeutic solutions that can prevent the severe disability associated with limb loss. The sheer scale of this public health crisis compels healthcare providers to adopt aggressive revascularization protocols rather than resorting to primary amputation. This clinical burden is quantitatively immense; according to the Society for Vascular Surgery, February 2024, in the 'New Data: 70% of Americans Unaware of Common Vascular Disease' press release, peripheral artery disease contributes to approximately 400 amputations performed each day in the United States alone. Consequently, the market is witnessing a surge in procedure volumes as hospitals prioritize limb salvage programs to address these alarmingly high morbidity statistics and improve quality of life for the geriatric and diabetic patient bases.

Download Free Sample Report

Key Market Challenges

The primary impediment to the Global Critical Limb Ischemia Treatment Market is the high frequency of procedural failures resulting in amputation, which creates a substantial barrier to the adoption of advanced revascularization therapies. When interventions fail to restore sufficient blood flow, the resulting limb loss represents a perceived inefficiency in healthcare spending. This correlation between expensive treatment attempts and eventual amputation causes payers to scrutinize the cost-effectiveness of premium medical devices. Consequently, insurance bodies often limit reimbursement for high-cost salvage techniques in complex cases, directly hampering revenue potential for manufacturers.

The severity of these outcomes reinforces the reluctance within the healthcare sector to authorize aggressive spending on patients with poor prognoses. According to the American Heart Association, in its 2024 Heart Disease and Stroke Statistics report, nearly 50% of adults aged 65 and older who underwent limb amputation died within one year of the surgery. This high mortality rate highlights the heavy clinical and economic burden on medical systems associated with failed limb salvage. Faced with such statistics, purchasing committees often prioritize lower-cost protocols over novel technologies, restricting the addressable market for new treatments.

Key Market Trends

The Migration to Office-Based Interventional Suites is fundamentally altering the service delivery model for revascularization as providers seek to minimize overhead costs while maintaining high procedural volumes. This shift is heavily incentivized by updated reimbursement structures that increasingly favor ambulatory surgical centers (ASCs) for performing peripheral arterial interventions, thereby decanting lower-risk critical limb ischemia cases from burdened hospital settings. According to the Ambulatory Surgery Center Association, November 2024, in the 'CMS Releases 2025 Final Payment Rule' announcement, the Centers for Medicare & Medicaid Services finalized an effective payment update of 2.9% for ASCs, sustaining the financial viability of performing complex vascular procedures in these streamlined outpatient environments.

The Utilization of Advanced AI-Driven Imaging Modalities is addressing the clinical need for precision guidance during complex endovascular recanalizations where traditional 2D fluoroscopy often falls short. Innovations in fiber optic and AI-enhanced visualization allow physicians to navigate tortuous anatomies with three-dimensional, radiation-free tracking, significantly improving procedural safety and efficiency for limb-threatening conditions. According to Royal Philips, September 2024, in the 'Philips announces FDA approval for enhanced LumiGuide guidewire' press release, clinical usage data demonstrated that the company's fiber optic guidance technology enabled complex vascular procedures to be completed 37% faster while reducing X-ray imaging use by 70% compared to conventional methods.

Segmental Insights

Embolic protection devices currently represent the fastest growing segment within the global critical limb ischemia treatment market due to an increasing emphasis on procedural safety during endovascular interventions. As physicians perform complex atherectomy and stenting procedures to restore blood flow, the risk of distal embolization remains a significant clinical concern. These devices effectively capture dislodged plaque debris, thereby preventing downstream blockages and reducing the likelihood of adverse events. Consequently, market adoption has surged, supported by clearances from regulatory authorities such as the U.S. Food and Drug Administration that validate their efficacy in peripheral vascular applications.

Regional Insights

North America maintains the leading position in the global Critical Limb Ischemia Treatment Market, primarily due to the high prevalence of peripheral artery disease and diabetes within the United States. This dominance is supported by favorable reimbursement frameworks established by the Centers for Medicare & Medicaid Services, which enable widespread access to revascularization procedures. Furthermore, the region benefits from a concentrated presence of major medical device manufacturers that actively secure product approvals from the U.S. Food and Drug Administration. These elements, combined with established healthcare infrastructure, ensure North America remains the primary revenue generator in this sector.

Recent Developments

• In November 2024, Endologix LLC announced the final 36-month results from the DETOUR2 clinical study, which evaluated the safety and effectiveness of the DETOUR System for percutaneous transmural arterial bypass. The data, presented at a major vascular conference, highlighted the system's durability in treating complex peripheral arterial disease in the superficial femoral artery, a condition that can progress to critical limb ischemia. The study reported a high rate of freedom from major lower limb amputation and symptomatic deep venous thrombosis. These long-term results support the system's role as a minimally invasive alternative to traditional open surgical bypass for patients with severe arterial blockages.
• In May 2024, Johnson & Johnson completed the acquisition of Shockwave Medical for an enterprise value of approximately $13.1 billion. This strategic transaction expanded the company's MedTech portfolio into the high-growth cardiovascular intervention segment, specifically adding Shockwave's intravascular lithotripsy (IVL) technology. This technology is utilized to treat calcified plaque in coronary and peripheral arteries, a common complication in patients with critical limb ischemia and peripheral artery disease. The integration of this platform is expected to accelerate the development of treatments for complex vascular diseases and strengthen the company's position in the global market.
• In May 2024, Surmodics, Inc. entered into a definitive agreement to be acquired by the private equity firm GTCR for $43.00 per share in cash, valuing the transaction at approximately $627 million. Surmodics is a key provider of medical device technologies, including drug-coated balloons used in the treatment of peripheral artery disease, a precursor to critical limb ischemia. This acquisition is anticipated to provide the company with the resources to further invest in its product pipeline and commercial expansion. The deal underscores the continued investment interest in companies developing specialized technologies for vascular interventions.
• In April 2024, Abbott announced that the U.S. Food and Drug Administration (FDA) approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System. This approval marked a significant advancement in the Global Critical Limb Ischemia Treatment Market, as the device is the first of its kind designed to treat chronic limb-threatening ischemia below the knee. The system functions by keeping arteries open to deliver a drug that supports vessel healing before completely dissolving over time. The approval was supported by results from the LIFE-BTK trial, which demonstrated that the scaffold offered superior outcomes compared to balloon angioplasty, the former standard of care for this condition.

Key Market Players

• Medtronic Plc
• LimFlow SA
• Cynata Therapeutics Ltd
• Cardiovascular Systems, Inc.
• Eli Lilly and Company
• Abbott Laboratories
• Rexgenero Ltd.
• ThermoGenesis Holdings, Inc
• Teva Pharmaceuticals
• Micro Medical Solutions
• Boston Scientific Corporation

By Treatment	By Region
Drugs {Antiplatelet Drugs Antihypertensive Agents Lipid-lowering Agents Antithrombotic Agents Others} Devices {Embolic Protection Devices Peripheral Dilatation System Balloon Dilators Vascular Stents}	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Critical Limb Ischemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Critical Limb Ischemia Treatment Market, By Treatment:

• Drugs {Antiplatelet Drugs
• Antihypertensive Agents
• Lipid-lowering Agents
• Antithrombotic Agents
• Others}
• Devices {Embolic Protection Devices
• Peripheral Dilatation System
• Balloon Dilators
• Vascular Stents}

• Critical Limb Ischemia Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE